Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study

Fertility and Sterility

Volumn 87, Issue 6, 2007, Pages 1267-1270

  Goldstein, Jerald ^a   Cushman, Mary ^b   Badger, Gary J ^c   Johnson, Julia V ^c  

^a Neurology Specialists of Dallas   (United States)

^b Radiation Oncology   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 8 CONCENTRATE; C REACTIVE PROTEIN; D DIMER; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR;

ADULT; BLOOD COAGULATION; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MEDROXYPROGESTERONE; PARTIAL THROMBOPLASTIN TIME; PILOT PROJECTS; PROSPECTIVE STUDIES; REFERENCE VALUES;

EID: 34249751711     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.11.040     Document Type: Article

References (21)

1. Inman W.H., Vessey M.P., Westerholm B., and Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 2 (1970) 203-209
2. Lidegaard O., and Kreiner S. Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception 65 (2002) 197-205
3. Lidegaard O., Edstrom B., and Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 65 (2002) 187-196
4. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study. Contraception 57 (1998) 315-324
5. United Nations Development Programme. Comparative study of the effects of two once-a-month injectable contraceptives (Cyclofem and Mesigyna) and one oral contraceptive (Ortho Novem 1/35) on coagulation and fibrinolysis. Contraception 68 (2003) 159-176
6. Declerck P.J., Mombaerts P., Holvoet P., De Mol M., and Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost 58 (1987) 1024-1029
7. Tripodi A., Chantarangkul V., Martinelli I., Bucciarelli P., and Mannucci P.M. A shortened activated partial thromboplastin time is associated with the risk of venous thromboemolism. Blood 104 (2004) 3631-3634
8. Danesh J., Whincup P., Walker M., et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 103 (2001) 2323-2327
9. Folsom A.R., Aleksic N., Park E., Salomaa V., Juneja H., and Wu K.K. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 21 (2001) 611-617
10. Ridker P.M., Hennekens C.H., Cerskus A., and Stampfer M.J. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 90 (1994) 2236-2240
11. Cushman M., Lemaitre R.N., Kuller L.H., et al. Fibrinolytic activation markers predict myocardial infarction in the elderly: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 19 (1999) 493-498
12. Andreescu A.C., Cushman M., and Rosendaal F.R. D-Dimer as a risk factor for deep vein thrombosis: the Leiden thrombophilia study. Thromb Haemost 87 (2002) 47-51
13. Cushman M., Folsom A.R., Wang L., Aleksic N., Rosamond W.D., Tracey R.P., and Heckbert S.R. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 101 (2004) 1243-1248
14. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 (2001) 2481-2485
15. Harris T.B., Ferrucci L., Tracy R.P., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106 (1999) 506-512
16. Tracy R.P., Psaty B.M., Macy E., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 17 (1997) 2167-2176
17. Yamamoto H., Noguchi S., Miyauchi K., et al. Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer. Jpn J Cancer Res 82 (1991) 420-425
18. Fahmy K., Khairy M., Allam G., Gobran F., and Alloush M. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 44 (1991) 431-444
19. Wiegratz I., Lee J.H., Kutschera E., Winkler U.H., and Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception 70 (2004) 97-106
20. Kawano H., Motoyama T., Hirai N., et al. Effect of medroxyprogesterone acetate plus estradiol on endothelium-dependent vasodilation in postmenopausal women. Am J Cardiol 87 (2001) 238-240
21. Kjaeldgaard A., Ahlesteen I., Larsson B., and Astedt B. Progestogen regulation of tissue plasminogen activator in a human melanoma cell line. Thromb Res 49 (1988) 287-297